BIOMAT Database Logo BIOMAT Database Logo

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. 1995

J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties
D013921 Thrombocytopenia A subnormal level of BLOOD PLATELETS. Thrombopenia,Thrombocytopenias,Thrombopenias
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug

Related Publications

J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
October 1992, Chest,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Oral contraceptives: mechanism of action, dosing, safety, and efficacy.
January 2008, Cutis,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
January 2007, HIV medicine,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action.
January 1982, Pharmacotherapy,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.
January 1983, Pharmacotherapy,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Suboptimal monitoring and dosing of unfractionated heparin.
April 2004, Annals of internal medicine,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.
January 1986, Pharmacotherapy,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
September 2008, Pharmacotherapy,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
January 2018, Reviews in cardiovascular medicine,
J Hirsh, and R Raschke, and T E Warkentin, and J E Dalen, and D Deykin, and L Poller
Mechanism of action, potency and efficacy: considerations for cell therapies.
May 2024, Journal of translational medicine,
Copied contents to your clipboard!